Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2009 1
2010 3
2011 2
2013 1
2015 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Left atrial remodeling and response to valsartan in the prevention of recurrent atrial fibrillation: the GISSI-AF echocardiographic substudy.
Staszewsky L, Wong M, Masson S, Raimondi E, Gramenzi S, Proietti G, Bicego D, Emanuelli C, Pulitanò G, Taddei F, Nicolis EB, Correale E, Fabbri G, Bertocchi F, Franzosi MG, Maggioni AP, Tognoni G, Disertori M, Latini R; GISSI-AF Investigators. Staszewsky L, et al. Circ Cardiovasc Imaging. 2011 Nov;4(6):721-8. doi: 10.1161/CIRCIMAGING.111.965954. Epub 2011 Sep 16. Circ Cardiovasc Imaging. 2011. PMID: 21926261 Clinical Trial.
Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.
Latini R, Masson S, Pirelli S, Barlera S, Pulitano G, Carbonieri E, Gulizia M, Vago T, Favero C, Zdunek D, Struck J, Staszewsky L, Maggioni AP, Franzosi MG, Disertori M; GISSI-AF Investigators. Latini R, et al. J Intern Med. 2011 Feb;269(2):160-71. doi: 10.1111/j.1365-2796.2010.02287.x. Epub 2010 Oct 22. J Intern Med. 2011. PMID: 20964739 Free article. Clinical Trial.
Valsartan for prevention of recurrent atrial fibrillation.
GISSI-AF Investigators; Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. GISSI-AF Investigators, et al. N Engl J Med. 2009 Apr 16;360(16):1606-17. doi: 10.1056/NEJMoa0805710. N Engl J Med. 2009. PMID: 19369667 Free article. Clinical Trial.
Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial.
Masson S, Aleksova A, Favero C, Staszewsky L, Bernardinangeli M, Belvito C, Cioffi G, Sinagra G, Mazzone C, Bertocchi F, Vago T, Peri G, Cuccovillo I, Masuda N, Barlera S, Mantovani A, Maggioni AP, Franzosi MG, Disertori M, Latini R; GISSI-AF investigators. Masson S, et al. Heart. 2010 Dec;96(23):1909-14. doi: 10.1136/hrt.2009.191460. Epub 2010 Oct 21. Heart. 2010. PMID: 20965978 Clinical Trial.
Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial.
Staszewsky L, Masson S, Barlera S, Disertori M, Boni S, Bertoli D, Vriz O, Pasotti E, Zeni P, Vago T, Maggioni AP, Tognoni G, Latini R; on the behalf of the GISSI-AF Investigators. Staszewsky L, et al. Cardiovasc Drugs Ther. 2015 Dec;29(6):551-561. doi: 10.1007/s10557-015-6624-3. Cardiovasc Drugs Ther. 2015. PMID: 26546322
Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M, Latini R, Maggioni AP, Delise P, Di Pasquale G, Franzosi MG, Staszewsky L, Tognoni G; GISSI-AF Investigators. Disertori M, et al. J Cardiovasc Med (Hagerstown). 2006 Jan;7(1):29-38. doi: 10.2459/01.JCM.0000199778.85343.08. J Cardiovasc Med (Hagerstown). 2006. PMID: 16645357 Clinical Trial.